ISRCTN14235381已完成2 期
Efficacy and safety of the S 05985 combination compared with each individual component: randomised, double-blind, placebo-controlled study over eight weeks in hypertensive patients
Institut de Recherches Internationales Servier (France)0 个研究点目标入组 1,581 人开始时间: 2008年1月23日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 1,581
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Men or women
- •2. 18 to 80 years
- •3. Essential uncomplicated mild to moderate hypertensive patients
排除标准
- •1. Very high cardiovascular risk patients
- •2. Severe disease
- •3. Pregnancy
- •4. Obesity
- •5. Secondary hypertension
研究者
相似试验
已完成
4 期
A clinical evaluation of safety of combination therapy with Rapid Onset Opioid and Short Acting Opioid.Cancer PainJPRN-UMIN000019224Kansai Electric Power Hospital30
已完成
不适用
Investigation on efficacy and safety of combination treatment with imidafenacin and mirabegron in patients with overactive bladder.overactive bladderJPRN-UMIN000016236Clinical Research Support Center Kyushu30
已完成
2 期
A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel with MORAb-004 in Metastatic Soft Tissue Sarcomasoft tissue cancer10072990NL-OMON39691Morphotek, Inc10
进行中（未招募）
1 期
A clinical trial that is evaluating how safe and effective an experimental treatment called MORAb-004 is when used in combination with Gemcitabine and Docetaxel in patients diagnosed with Metastatic Soft Tissue Sarcoma.EUCTR2012-001399-12-NLMorphotek Inc.200
进行中（未招募）
1 期
A clinical trial that is evaluating how safe and effective an experimental treatment called MORAb-004 is when used in combination with Gemcitabine and Docetaxel in patients diagnosed with Metastatic Soft Tissue Sarcoma.Metastatic Soft Tissue SarcomaMedDRA version: 15.1Level: HLGTClassification code 10041299Term: Soft tissue sarcomasSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001399-12-BEMorphotek Inc.200